Stocks Market
Promopharm H1 2026: Net Profit Plunges 74% Despite 9% Revenue Growth as Strategic Investments Weigh
Moroccan pharmaceutical giant Promopharm reported a sharp 74% year-on-year decline in net profit to MAD 6.8 million for the first half of 2026, even as revenue climbed 9% to MAD 507 million. The earnings miss stems from heavy depreciation and financing costs tied to the new injectable production unit launched in late 2025, alongside ramped-up R&D spending. Management maintains its growth trajectory, targeting portfolio expansion and industrial capacity upgrades in the second half.
Listen to this article
Unlock audio versions of premium articles and more with a Pro subscription.
Promopharm's H1 2026 Results: Revenue Up, Profits Down Amid Strategic Transformation
Casablanca-listed pharmaceutical manufacturer Promopharm unveiled its half-year results for 2026 on September 29, revealing a stark divergence between top-line growth and bottom-line performance. While revenue advanced 9% year-on-year to MAD 507 million, net profit collapsed 74% to MAD 6.8 million from MAD 26.3 million in H1 2025.
Investment Cycle Weighs on Near-Term Profitability
The board attributed the profit erosion primarily to the commissioning of a new injectable production facility at end-2025. This strategic asset has triggered a step-up in depreciation charges and associated financing costs. Concurrently, the company has intensified R&D expenditure to enrich its product pipeline and secure future growth drivers.
- Revenue: MAD 507M (+9% YoY)
- Net Profit: MAD 6.8M (-74% YoY)
- Key Drivers: New product launches, ramp-up of recent introductions
- Profit Pressures: Depreciation from new injectable unit, higher financing costs, elevated R&D spend
Outlook: Staying the Course on Growth Strategy
Despite the earnings hit, Promopharm reiterated its commitment to a three-pillar strategy for H2 2026: expanding its product portfolio, strengthening industrial capabilities, and improving patient access to quality treatments. The market will be watching for signs of operating leverage as the new facility reaches cruising speed and R&D investments begin to convert into commercialized products.
Note: Promopharm had previously issued a profit warning ahead of this release.